The need for vaccination in adults with chronic (noncommunicable) diseases in India - lessons from around the world
Worldwide, chronic diseases (noncommunicable diseases [NCDs]) cause 41 million (71%) deaths annually. They are the leading cause of mortality in India, contributing to 60% of total deaths each year. Individuals with these diseases are more susceptible to vaccine-preventable diseases (VPDs) and have an increased risk of associated disease severity and complications. This poses a substantial burden on healthcare systems and economies, exemplified by the COVID-19 pandemic. Vaccines are an effective strategy to combat these challenges; however, utilization rates are inadequate. With India running one of the world's largest COVID-19 vaccination programs, this presents an opportunity to improve vaccination coverage for all VPDs. Here we discuss the burden of VPDs in those with NCDs, the benefit of vaccinations, current challenges and possible strategies that may facilitate implementation and accessibility of vaccination programs. Effective vaccination will have a significant impact on the disease burden of both VPDs and NCDs and beyond.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
Human vaccines & immunotherapeutics - 18(2022), 5 vom: 30. Nov., Seite 2052544 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Vora, Agam [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 Vaccines |
|---|
| Anmerkungen: |
Date Completed 17.06.2022 Date Revised 03.10.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/21645515.2022.2052544 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM339462760 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM339462760 | ||
| 003 | DE-627 | ||
| 005 | 20231226204512.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/21645515.2022.2052544 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1131.xml |
| 035 | |a (DE-627)NLM339462760 | ||
| 035 | |a (NLM)35416747 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Vora, Agam |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The need for vaccination in adults with chronic (noncommunicable) diseases in India - lessons from around the world |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.06.2022 | ||
| 500 | |a Date Revised 03.10.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Worldwide, chronic diseases (noncommunicable diseases [NCDs]) cause 41 million (71%) deaths annually. They are the leading cause of mortality in India, contributing to 60% of total deaths each year. Individuals with these diseases are more susceptible to vaccine-preventable diseases (VPDs) and have an increased risk of associated disease severity and complications. This poses a substantial burden on healthcare systems and economies, exemplified by the COVID-19 pandemic. Vaccines are an effective strategy to combat these challenges; however, utilization rates are inadequate. With India running one of the world's largest COVID-19 vaccination programs, this presents an opportunity to improve vaccination coverage for all VPDs. Here we discuss the burden of VPDs in those with NCDs, the benefit of vaccinations, current challenges and possible strategies that may facilitate implementation and accessibility of vaccination programs. Effective vaccination will have a significant impact on the disease burden of both VPDs and NCDs and beyond | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a India | |
| 650 | 4 | |a NCDs | |
| 650 | 4 | |a VPDs | |
| 650 | 4 | |a chronic disease | |
| 650 | 4 | |a infectious disease | |
| 650 | 4 | |a noncommunicable disease | |
| 650 | 4 | |a vaccination | |
| 650 | 4 | |a vaccine-preventable disease | |
| 650 | 4 | |a vaccines | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 700 | 1 | |a Di Pasquale, Alberta |e verfasserin |4 aut | |
| 700 | 1 | |a Kolhapure, Shafi |e verfasserin |4 aut | |
| 700 | 1 | |a Agrawal, Ashish |e verfasserin |4 aut | |
| 700 | 1 | |a Agrawal, Someya |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Human vaccines & immunotherapeutics |d 2012 |g 18(2022), 5 vom: 30. Nov., Seite 2052544 |w (DE-627)NLM21576823X |x 2164-554X |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2022 |g number:5 |g day:30 |g month:11 |g pages:2052544 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/21645515.2022.2052544 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2022 |e 5 |b 30 |c 11 |h 2052544 | ||